ORCHPHARMA
Orchid Pharma Limited
Each stock's 10,000-path forecast, rendered as light.
Orchid Pharma Limited (ORCHPHARMA) Stock Analysis & Case Study
Is ORCHPHARMA a good buy? The data-driven verdict.
Orchid Pharma Limited (ORCHPHARMA) trades at ₹1,002,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 28/100.
On the numbers, Orchid Pharma Limited (ORCHPHARMA) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing expensive at 352.0× earnings, ROE of 2.1%, a 53% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
ORCHPHARMA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How ORCHPHARMA ranks against the 2,373 companies in our screener
- ORCHPHARMA's market cap of 9,548 Cr ranks in the 75th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ORCHPHARMA's book value of ₹254 ranks in the 77th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ORCHPHARMA's promoter holding of 69.8% ranks in the 73rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ORCHPHARMA's 3-year profit (PAT) growth of 63.0% ranks in the 88th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ORCHPHARMA's 3-year revenue growth of 7.0% ranks in the 41st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ORCHPHARMA's debt-to-equity ratio of 0.28x is lower than 54% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is ORCHPHARMA overvalued? ORCHPHARMA P/E vs peers
ORCHPHARMA trades at 352.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
ORCHPHARMA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of ORCHPHARMA history (21%/yr drift, 47%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ORCHPHARMA 2027 | ₹575 | ₹1,042 | ₹1,887 | +4% |
| ORCHPHARMA 2028 | ₹463 | ₹1,083 | ₹2,535 | +8% |
| ORCHPHARMA 2029 | ₹399 | ₹1,126 | ₹3,178 | +12% |
| ORCHPHARMA 2030 | ₹360 | ₹1,171 | ₹3,812 | +17% |
| ORCHPHARMA 2031 | ₹325 | ₹1,218 | ₹4,566 | +22% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ORCHPHARMA goes up, or doubles?
The bull case for ORCHPHARMA
- Orchid Pharma Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,178.
The bear case & risks
- ORCHPHARMA's P/E of 352.0x is lower than 3% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ORCHPHARMA's return on equity of 2.1% ranks in the 20th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (47%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹399.
ORCHPHARMA volatility & expected range, how bumpy is the ride?
Over the last 9.8 years ORCHPHARMA compounded at 21%/year with annualized volatility of 47%. That volatility implies a 1-year 80% range of ₹575-₹1,887, the honest backbone behind any single price target.
ORCHPHARMA price forecast, the full 60-month probability fan
ORCHPHARMA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ORCHPHARMA hits common targets within the simulated horizon?
Full multi-horizon detail on the ORCHPHARMA price target & forecast page.
ORCHPHARMA Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. ORCHPHARMA scores 5/8, mixed financial health.
ORCHPHARMA MTF margin & leverage across 7 brokers
Margin Trading Facility lets you buy ORCHPHARMA with part of the capital. Lower margin % = higher leverage. Rates compared across 7 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| ZerodhaCHEAPEST | 36.13% | 2.8× |
| Groww | 36.35% | 2.8× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 100.00% | 1.0× |
| Pocketful | 36.64% | 2.7× |
| Anand Rathi | 100.00% | 1.0× |
| Share India | 36.30% | 2.8× |
Compare every broker on the ORCHPHARMA MTF page.
About Orchid Pharma Limited: sector, index & market-cap context
Orchid Pharma Limited (ORCHPHARMA) is a small-cap NSE-listed company, with a market capitalisation of ₹9,548 Cr. See more stocks on our screener.
How the ORCHPHARMA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Orchid Pharma Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ORCHPHARMA analysis, FAQs
Is Orchid Pharma Limited (ORCHPHARMA) a good buy?
On the numbers, Orchid Pharma Limited (ORCHPHARMA) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing expensive at 352.0× earnings, ROE of 2.1%, a 53% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ORCHPHARMA overvalued or undervalued?
ORCHPHARMA trades at 352.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the ORCHPHARMA share price target for 2031?
ORCHPHARMA's probability-weighted 2031 median target is ₹1,218, with an 80% range of ₹325-₹4,566 (10,000-path Monte-Carlo).
What is the probability ORCHPHARMA doubles in 5 years?
The modelled probability of ORCHPHARMA reaching ₹2,004 (2×) within 5 years is 32%.
What is the bull case for ORCHPHARMA?
Orchid Pharma Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in ORCHPHARMA?
ORCHPHARMA's P/E of 352.0x is lower than 3% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. ORCHPHARMA's return on equity of 2.1% ranks in the 20th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (47%/yr) means a wide, bumpy range of outcomes, size positions accordingly.